Dr Helen Tayton-Martin has served as Chief Business & Strategy Officer of Adaptimmune since October 2022 and is a member of the Executive Team. As CBSO, Dr Tayton-Martin is responsible for optimizing the strategic and commercial opportunities for Adaptimmune’s assets, leading business development, competitive intelligence and alliance management. Her role encompasses all aspects of pipeline and technology assessment, strategic portfolio analysis and partnerships, including the company’s strategic partnerships with Astellas, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and GlaxoSmithKline (LSE/NYSE: GSK).
Dr Tayton‑Martin has 30 years of experience working within the pharma, biotech and consulting environment in disciplines across preclinical and clinical development, outsourcing, strategic planning, due diligence, business development and company operations. She co‑founded Adaptimmune from the former company, Avidex Limited, where she had been responsible for the business development of the soluble TCR program in cancer and HIV from 2005 to 2008.